DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9txlwf/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AmpliPhi Biosciences Corporation
- Applied Genetic Technologies Corporation
- BBB Therapeutics B.V.
- ProQR Therapeutics N.V.
- QLT Inc.
- Spark Therapeutics, Inc.
- Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1
- Small Molecules for Inherited Retinal Diseases
For more information visit http://www.researchandmarkets.com/research/9txlwf/leber_congenital